CSPC Pharma's ALMB-0166 advances to China clinical trials for Parkinson's

CSPC Pharmaceutical Group Limited announced that its internally developed drug, ALMB-0166, has secured approval from China's National Medical Products Administration to commence phase II clinical trials. The trial will evaluate ALMB-0166's efficacy in patients suffering from Parkinson's disease.

ALMB-0166 is a first-in-class humanized monoclonal antibody, developed by CSPC's subsidiary, AlaMab Therapeutics Inc. It targets the novel hemichannel membrane protein Connexin 43 (Cx43) and is intended for the treatment of Parkinson's disease, acute ischemic stroke, acute spinal cord injury, and other neurological disorders. Preclinical studies have shown that ALMB-0166 prevents dopamine depletion, restores behavioral performance, and demonstrates a favorable dose-response in animal models.

Parkinson's disease is the second most common neurodegenerative disorder globally, currently lacking curative treatments. Current therapies primarily offer symptomatic relief. This development highlights the urgent need for novel approaches to delay disease progression and enhance patients' quality of life.